Trinity Biotech Launches Trinovium for AI Data Center Cooling

Trinity Biotech has launched Trinovium, a new subsidiary targeting the liquid cooling market for AI and high-performance computing data centers, according to a company announcement reported by StockTitan.

The Dublin-based diagnostics company is redirecting a portion of its existing U.S. and European manufacturing capacity—currently producing millions of liters of high-precision fluids annually for medical applications—to serve data center operators facing thermal management challenges as compute density increases.

Trinovium's initial product is a direct-to-chip liquid coolant formulated around ultra-high purity chemistry, corrosion protection, and healthcare-grade consistency standards aligned with Open Compute Project guidelines. The company plans to add a fluid health monitoring platform that uses electrochemical sensing and mass spectrometry to track corrosion, contamination, and microbial growth in cooling systems.

Market opportunity and timing

The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, representing a compound annual growth rate of 31.5 percent, according to MarketsandMarkets research cited in the announcement. The shift from air to liquid cooling is accelerating as advanced GPU architectures push power loads beyond the thermal limits of conventional cooling methods.

Trinity Biotech CEO John Gillard, who previously held senior roles at Google and other large-scale infrastructure companies, said the strategy leverages the company's existing capabilities in ultra-high-purity fluid manufacturing. "We are applying what we do today at an exceptionally high standard to AI infrastructure—one of the fastest-growing segments of global compute," Gillard stated.

Why it matters

The launch illustrates how companies with adjacent manufacturing capabilities are entering the AI infrastructure supply chain as thermal management becomes a bottleneck for hyperscale deployments. Trinity's move is capital-efficient because it repurposes existing production lines rather than building new facilities, potentially offering faster time-to-market than greenfield competitors. The planned monitoring platform also positions Trinovium to capture recurring revenue through performance analytics, not just one-time fluid sales—a business model shift that could appeal to investors looking for predictable cash flows in AI infrastructure plays.

Parallel operations

Trinity Biotech continues to commercialize its core healthcare portfolio, including FDA 510(k)-cleared diabetes and hemoglobin analyzers, WHO-prequalified HIV rapid tests, and a continuous glucose monitoring solution under development. The company described its operational transformation plan as nearing completion, enabling the capacity reallocation to Trinovium.

Following the announcement, Trinity Biotech's stock rose 24.23 percent to $0.72 on volume 49 times the average, adding approximately $2 million to the company's $11.79 million market capitalization, according to StockTitan data.

Details were first reported by StockTitan based on Trinity Biotech's June 23 press release.